FREE RAC Postmarket Surveillance and Compliance Questions and Answers

Question 1

A manufacturer becomes aware that a series of malfunctions with its infusion pump necessitates a nationwide field correction to prevent an unreasonable risk of substantial public harm. The company also has information reasonably suggesting these malfunctions may have contributed to a patient's death. According to 21 CFR 803, what is the mandatory reporting timeframe to the FDA for this event?

Accepted Answer

5 working days after becoming aware that a reportable event requires remedial action.

Answer

According to 21 CFR 803.53, a manufacturer must submit a 5-day report if they become aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. The need for a nationwide field correction to prevent such harm triggers this expedited reporting requirement.

Question 2

Under the EU Medical Device Regulation (MDR 2017/745), which of the following BEST describes the purpose of the Post-Market Surveillance Report (PMSR)?

Accepted Answer

To summarize the results and conclusions of post-market surveillance data analysis primarily for Class I devices.

Answer

The PMSR, as defined in Article 85 of the EU MDR, is required for Class I devices. It is a summary of the results and conclusions of the analyses of the post-market surveillance data. For higher-risk devices (Class IIa, IIb, and III), a more comprehensive Periodic Safety Update Report (PSUR) is required.

Question 3

A pharmaceutical company holds an approved New Drug Application (NDA). Which of the following is considered an "unexpected" adverse drug experience that would require an expedited 15-day "Alert Report" to the FDA?

Accepted Answer

An adverse event that is listed in the current product labeling, but is now occurring with greater severity.

Answer

Per 21 CFR 314.80(a), an "unexpected" adverse drug experience is one not listed in the current labeling. The definition explicitly includes events that may be related to an event in the labeling but differ because of greater severity or specificity. The Investigator's Brochure is not the same as the approved labeling, and non-serious or expected events do not trigger the 15-day reporting requirement.

Question 4

A medical device manufacturer identifies a software anomaly in its patient monitoring system that may, in rare circumstances, cause a temporary, 5-second data lag. This could theoretically lead to a brief delay in clinical intervention. The manufacturer initiates a voluntary correction. How would the FDA MOST likely classify this recall?

Accepted Answer

Class II

Answer

A Class II recall applies to situations where the use of a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The scenario describes a potential for temporary harm (delay in intervention), but serious harm is not a reasonable probability, fitting the Class II definition.

Question 5

The FDA has ordered a manufacturer to conduct a postmarket surveillance study under Section 522 of the FD&C Act for its permanently implantable device. This mandatory study is MOST likely intended to answer a specific question about the device's:

Accepted Answer

long-term performance and safety.

Answer

Section 522 of the FD&C Act grants the FDA authority to require manufacturers to conduct postmarket surveillance to gather specific data on a device's long-term safety and effectiveness. These studies are ordered to address important public health questions that could not be fully answered with premarket data.

(RAC) Regulatory Affairs Certification Practice Test

(RAC) Regulatory Affairs Certification Practice Test

FREE RAC Postmarket Surveillance and Compliance Questions and Answers